


CLAIMS

What is claimed is:

1. A compound, being a compound represented by Formula I; or being a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of the compound represented by Formula

5 I,



wherein,

R¹ and R² are each independently selected from -H or -CH₃,

provided that:


10 when R¹ and R² are not -H simultaneously; or


when R¹ and R² are not -CH₃ simultaneously.

2. The compound according to claim 1, wherein R¹ is -H, and R² is -CH₃.

3. The compound according to claim 1, wherein R¹ is -CH₃, and R² is -H.

4. The compound according to claim 1, wherein the compound is one of the following
15 compounds; or a tautomer, a stereoisomer, a hydrate, a solvate, a salt, or a prodrug of one of following compounds,





5. A pharmaceutical composition, comprising the compound according to any one of claims 1 to 4 as an active ingredient.

6. Use of the compound according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5 in manufacture of a medicament for treating or preventing ATX-related diseases.

7. The use according to claim 6, wherein the ATX-related diseases comprise at least one selected from cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative diseases, dermatological disorder, and/or abnormal angiogenesis-related disease.

8. The use according to claim 6, wherein the ATX-related diseases comprise at least one selected from interstitial lung disease, pulmonary fibrosis, liver fibrosis, or renal fibrosis.

9. The use according to claim 6, wherein the ATX-related diseases comprise idiopathic pulmonary fibrosis.

10. The use according to claim 6, wherein the ATX-related diseases comprise type II diabetes and nonalcoholic steatohepatitis.

11. The use according to claim 6, wherein the ATX-related diseases comprise neuropathic pain and inflammatory pain.

12. The use according to claim 6, wherein the ATX-related diseases comprise osteoarthritis-related pain.

13. A drug combination, comprising:

the compound according to any one of claims 1 to 4 or the pharmaceutical composition according to claim 5; and

an additional drug for treating or preventing ATX-related diseases.

14. The compound according to any one of claims 1 to 4, the pharmaceutical composition according to claim 5, or the drug combination according to claim 13 for use in treating or

preventing ATX-related diseases, wherein the compound, the pharmaceutical composition, or the drug combination is to be administered to a patient.

15. The compound, the pharmaceutical composition, or the drug combination for use according to claim 14, wherein the ATX-related diseases comprise at least one selected from
- 5 cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative diseases, dermatological disorder, and/or abnormal angiogenesis-related disease.